Home / Psoriasis

Psoriasis

LEO Pharma and Research Project BIOMAP: Towards Personalized Medicine for Inflammatory Skin Diseases

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key …

Read More »

Novartis’ Cosentyx Shows Superior Improvements in Psoriasis Patients’ Quality of Life Versus Janssen’s Stelara

Basel, March 5, 2019 – Novartis, a global leader in immuno-dermatology and rheumatology, announced today additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara®* (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over …

Read More »

FDA Approves Janssen’s Tremfya One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

HORSHAM, PENNSYLVANIA, February 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. TREMFYA® (guselkumab) is the first FDA-approved medication of its kind to offer the One-Press patient-controlled …

Read More »

Novartis Data Show Psoriasis Patients Treated with Cosentyx Reported Improvements in Quality of Life Measures as Early as Week 4

EAST HANOVER, N.J., Jan. 28, 2019 /PRNewswire/ — Novartis announced today results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx® (secukinumab) 300 mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early …

Read More »

Amgen Submits BLA to the FDA for ABP 710, a Biosimilar Candidate to Infliximab

THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). “At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We’re leveraging our deep expertise and …

Read More »

Lilly Announces Positive Top-Line Results for Taltz vs. Humira in Head-to-Head Superiority Study in Patients with Psoriatic Arthritis

INDIANAPOLIS, Dec. 17, 2018 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira®(adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive. The SPIRIT-H2H …

Read More »

New Phase 3 Data Demonstrate Superiority of Tremfya vs Cosentyx in Delivering PASI 90 Responses in Plaque Psoriasis

VIENNA–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicentre, randomised, double-blind head-to-head Phase 3 study demonstrated …

Read More »

FDA Approves Sandoz’s Biosimilar Hyrimoz (adalimumab-adaz) for all Indications of Reference Medicine

Holzkirchen, Germany, October 31, 2018 – Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years …

Read More »

Study Finds Enbrel Monotherapy and Combination Therapy Both Superior to Methotrexate in Patients with Psoriatic Arthritis

THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psoriatic arthritis (PsA) were presented in a late-breaking poster session at the 2018 American College of Rheumatology (ACR)/Association of …

Read More »

New Three-Year Tremfya Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

LAS VEGAS, Oct. 19, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA® treatment achieved from week 52 (1 year) were maintained through week 156 (3 years) among …

Read More »